FDA clears first digital treatment for depression, but experts caution that research is still early
The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. Rejoyn, made by Otsuka Pharmaceutical and Click Therapeutics, is a smartphone app intended for use alongside antidepressant medications for people 22 and older who have a diagnosis of major depressive disorder. It employs a…